Extract from the Register of European Patents

EP About this file: EP3139903

EP3139903 - AQUEOUS OPHTHALMIC SOLUTION AND METHOD FOR TREATING DRY EYE SYNDROME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  31.05.2019
FormerGrant of patent is intended
Status updated on  02.01.2019
FormerRequest for examination was made
Status updated on  10.02.2017
FormerThe international publication has been made
Status updated on  04.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): AL
published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Croma-Pharma Gesellschaft m.b.H.
Industriezeile 6
2100 Leobendorf / AT
[2017/11]
Inventor(s)01 / PRINZ, Martin
Croma-Pharma Gesellschaft m.b.H.
Industriezeile 6
A-2100 Leobendorf / AT
 [2017/11]
Representative(s)Schwarz & Partner Patentanwälte GmbH
Patentanwälte
Wipplingerstraße 30
1010 Wien / AT
[N/P]
Former [2019/27]Schwarz & Partner Patentanwälte OG
Patentanwälte
Wipplingerstraße 30
1010 Wien / AT
Former [2017/11]Schwarz & Partner
Patentanwälte Wipplingerstraße 30
1010 Wien / AT
Application number, filing date15718956.404.05.2015
[2017/11]
WO2015EP59674
Priority number, dateEP2014016738107.05.2014         Original published format: EP 14167381
[2017/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015169728
Date:12.11.2015
Language:EN
[2015/45]
Type: A1 Application with search report 
No.:EP3139903
Date:15.03.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 12.11.2015 takes the place of the publication of the European patent application.
[2017/11]
Type: B1 Patent specification 
No.:EP3139903
Date:03.07.2019
Language:EN
[2019/27]
Search report(s)International search report - published on:EP12.11.2015
ClassificationIPC:A61K9/08, A61K47/02, A61K47/10, A61K47/18, A61K47/24, A61K47/26, A61K47/38, A61K47/61, A61K31/715, A61K51/06, B65D65/40, B65D81/26, A61K9/00
[2018/52]
CPC:
A61K9/0048 (EP,CN,KR,US); A61K51/06 (EP,CN,IL,US); A61K9/08 (CN,RU,US);
A61J1/05 (CN); A61J1/10 (KR); A61J1/14 (CN);
A61J1/1468 (CN,KR); A61K31/715 (EP,US); A61K31/722 (KR);
A61K47/02 (US); A61K47/10 (KR,US); A61K47/183 (KR,US);
A61K47/24 (US); A61K47/26 (KR,US); A61K47/36 (CN,RU);
A61K47/38 (KR,US); A61K47/61 (EP,US); A61P27/02 (EP,RU);
A61P27/04 (EP); B65D65/40 (US); B65D81/266 (US) (-)
Former IPC [2017/11]A61K9/00, A61K47/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/11]
Extension statesBA20.10.2016
ME20.10.2016
Validation statesMA20.10.2016
TitleGerman:WÄSSRIGE OPTHALMISCHE LÖSUNG UND VERFAHREN ZUR BEHANDLUNG VON TROCKENEM AUGENSYNDROM[2018/52]
English:AQUEOUS OPHTHALMIC SOLUTION AND METHOD FOR TREATING DRY EYE SYNDROME[2017/11]
French:SOLUTION OPHTALMIQUE AQUEUSE ET PROCÉDÉ POUR TRAITER LE SYNDROME DE L'OEIL SEC[2018/52]
Former [2017/11]WÄSSRIGE OPHTHALMISCHE LÖSUNG UND VERFAHREN ZUR BEHANDLUNG DES SICCA-SYNDROMS
Former [2017/11]SOLUTION AQUEUSE OPHTALMIQUE ET MÉTHODE DE TRAITEMENT DU SYNDROME DE L'OEIL SEC
Entry into regional phase20.10.2016National basic fee paid 
20.10.2016Designation fee(s) paid 
20.10.2016Examination fee paid 
Examination procedure20.10.2016Examination requested  [2017/11]
20.10.2016Date on which the examining division has become responsible
17.03.2017Amendment by applicant (claims and/or description)
03.01.2019Communication of intention to grant the patent
03.05.2019Fee for grant paid
03.05.2019Fee for publishing/printing paid
03.05.2019Receipt of the translation of the claim(s)
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
17.05.2017Renewal fee patent year 03
25.05.2018Renewal fee patent year 04
23.05.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL03.07.2019
MC03.07.2019
MT03.07.2019
CY04.05.2020
HR04.05.2020
LT04.05.2020
LU04.05.2020
LV04.05.2020
SK04.05.2020
SI05.05.2020
EE31.05.2020
NO31.05.2020
[2022/31]
Former [2022/29]MC03.07.2019
MT03.07.2019
CY04.05.2020
HR04.05.2020
LT04.05.2020
LU04.05.2020
LV04.05.2020
SK04.05.2020
SI05.05.2020
EE31.05.2020
NO31.05.2020
Former [2021/24]MC03.07.2019
CY04.05.2020
HR04.05.2020
LT04.05.2020
LU04.05.2020
LV04.05.2020
SK04.05.2020
SI05.05.2020
EE31.05.2020
NO31.05.2020
Former [2021/15]MC03.07.2019
CY04.05.2020
HR04.05.2020
LT04.05.2020
LU04.05.2020
LV04.05.2020
SK04.05.2020
EE31.05.2020
NO31.05.2020
Former [2021/10]MC03.07.2019
CY04.05.2020
HR04.05.2020
LT04.05.2020
LV04.05.2020
SK04.05.2020
EE31.05.2020
NO31.05.2020
Former [2021/07]LT04.05.2020
NO31.05.2020
Cited inInternational search[XD] WO2008077172  (CROMA PHARMA GES M B H et al.) [XD] 1,2,4,5,9,10 * page 5 * * page 6, paragraph 3 * * page 7, paragraph 3 * * page 9, paragraphs 1-3 * * page 12, paragraph 1 * * example 6 *
 [A]   GERHARD GARHFER ET AL: "Chitosan-N-Acetylcysteine Eye Drops", CATARACT & REFRACTIVE SURGERY TODAY EUROPE, 1 November 2011 (2011-11-01), pages 49 - 50, XP055145970, Retrieved from the Internet [retrieved on 20141013] [A] 1-20 * page 49 - page 50 *
 [A]   SCHMITZ ET AL: "Synthesis and characterization of a chitosan-N-acetyl cysteine conjugate", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 347, no. 1-2, 29 November 2007 (2007-11-29), pages 79 - 85, XP022369799, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2007.06.040 [A] 1-20 * page 79 - page 84; figure 1; table 1 *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2007.06.040
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.